Category: India


Postcards from Bangalore 
Posted on Sep 10, 2015

  Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai, Pune, and Bangalore. Our main focus was a visit with a major client, a CDMO with multiple facilities across the country. Here are a few

Top 10 Drug Products in India 
Posted on Jul 29, 2014

  Do you know which are the top branded drug products in India? We didn’t until we found this handy chart and article.  We took their IMS data a step further by compiling a new table that includes generic names, companies, and sales in US dollars.  A few quick observations: Cough/cold and antibiotics, both short-term

Indian pharma draws more FDA scrutiny 
Posted on Sep 13, 2013

    We’ve posted about the Indian pharmaceutical market before, but this report is downright shocking: U.S. inspectors visiting a factory in India owned by drugmaker Wockhardt Ltd in March found torn data records in a waste heap and urinals that emptied into an open drain in a bathroom six meters from the entrance to

Biocon Mylan Biogenerics Partnership 
Posted on Feb 14, 2013

Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars: Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus®), Lispro (the generic version of Eli Lilly’s Humalog®) and Aspart (the

Pfizer Biocon signals the end for biosimilars? Hardly… 
Posted on Mar 15, 2012

Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will revert to Biocon, and all insulin distributed under the brand name UniviaTM and GlarviaTM will be commercially available from Biocon Ltd. only, and will be

The Sandwich Shoppe is Closed 
Posted on Feb 07, 2011

There has been a lot of commentary this week on Pfizer’s announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that the decision was based on  Pfizer’s decision to exit therapeutic areas such as allergy, respiratory, and urology, which are based in Sandwich. Wall Street analysts loved

More Government Involvement in Pharma Industry 
Posted on Jan 04, 2011

The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil, Russia, and Russia again. Today we learn that the Indian government is reportedly looking to cap foreign direct investment in pharmaceutical (and related) companies to

More on Russia…Is the US Next? 
Posted on Dec 20, 2010

Last week we wrote about the Russian government’s desire to grow their national pharmaceutical infrastructure. Our reading of the situation is that the government will “suggest” that ex-Russia companies who want to do business in the country will be asked to build manufacturing plants, invest in local R&D, etc. Today, Novartis announced a $500 million

India, India, and more about India 
Posted on Dec 13, 2010

Here is a sample of announcements from today alone regarding the pharmaceutical industry in India: First, UK-based Reckitt Benckiser is acquiring Paras Pharmaceuticals for $726 million. Paras makes a variety of over-the-counter products for pain and cough and cold. Next, both Merck and Watson Pharma are making it very clear that they are interested in

The Indian Connection 
Posted on Nov 22, 2010

The Indian pharmaceutical market is highly fragmented. How can pharma companies make money? PharmaTimes characterizes the market for us in summary form.

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.